Background: Long-term outcomes for patients with adult idiopathic nephrotic syndrome correlate closely with steroid responsiveness. The aim of this prospective study was to evaluate the difference in serum proteomes between steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) patients and identify potential biomarkers for the prediction of SRNS. Methods: We performed a gel-based proteomic study of serum obtained from SRNS and SSNS patients and healthy controls at the time of presentation (n = 6 for each group). Proteins from the serum samples were separated using 2-D electrophoresis, digested in-gel and subjected to MALDI-TOF-MS/MS analysis. Further validation was performed utilizing Western blot and ELISA. The sensitivities and specificities of the candidate proteins for predicting SRNS were determined using receiver operating characteristic curves. Results: Thirteen differentially expressed proteins were identified as haptoglobin (Hp) with different isoelectric points and molecular weights. Western blot and ELISA analysis of samples from 146 subjects (healthy controls = 52, SSNS = 54, SRNS = 40) showed a markedly increased level of Hp in the serum, but not urine, of SRNS compared to SSNS patients. The optimal serum cutoff level of Hp was set at ≥1,279 µg/ml using the receiver operating characteristic curve. The sensitivity and specificity for predicting SRNS were 85.0 and 96.3%, respectively. Conclusions: This study provides a novel overview of the difference in serum proteomes of SSNS and SRNS patients. Serum Hp may be a useful predictive biomarker for steroid therapy efficacy in the treatment of idiopathic nephrotic syndrome.

1.
Tune BM, Mendoza SA: Treatment of the idiopathic nephritic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997;8:824–832.
2.
Ponticelli C, Passerini P, Altieri P, et al: Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 1992;7(suppl 1):85–90.
3.
Ghiggeri GM, Catarsi P, Scolari F, et al: Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther 2004;26:1411–1418.
4.
Meryl Waldman, R. John Crew, Anthony Valeri, et al: Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007;2:445–453.
5.
Mak SK, Short CD, Mallick NP: Long-term outcome of adult-onset minimal change nephropathy. Nephrol Dial Transplant 1996;11:2192–2201.
6.
Korbet SM, Rydel J, Schwartz M, et al: The prognosis of focal segmental glomerular sclerosis in adults. J Am Soc Nephrol 1993;4:280.
7.
Troyanov S, Wall CA, Miller JA, et al: Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005;16:1061–1068.
8.
Kimura M, Toyoda M, Kobayashi K, et al: A retrospective study on the efficacy of corticosteroid-alone therapy in membranous nephropathy patients. Intern Med 2007;46:1641–1645.
9.
Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–867.
10.
Chromy BA, Gonzales AD, Perkins J, Choi MW, et al: Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high- abundant proteins. J Proteome Res 2004;3:1120–1127.
11.
Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, et al: Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005;5:3790–3797.
12.
Khurana M, Traum AZ, Aivado M, et al: Urine proteomic profiling of pediatric nephrotic syndrome. Pediatr Nephrol 2006;21:1257–1265.
13.
Woroniecki RP, Orlova TN, Mendelev N, et al: Urinary proteome of steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome of childhood. Am J Nephrol 2006;26:258–267.
14.
Haugen TH, Hanley JM, Heath EC: Haptoglobin: a novel mode of biosynthesis of a liver secretory glycoprotein. J Biol Chem 1981;256:1055–1057.
15.
Engstrom G, Stavenow L, Hedblad B, et al: Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 2003;52:42–447.
16.
D’Armiento J, Dalal SS, Chada K: Tissue, temporal and inducible expression pattern of haptoglobin in mice. Gene 1997;195:19–27.
17.
Cid MC, Grant DS, Hoffman GS, et al: Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993;91:977–985.
18.
Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589–1600.
19.
Tencer J, Thysell H, Westman K, Rippe B: Elevated plasma levels of acute phase proteins in mesangioproliferative glomerulonephritis, membranous nephropathy and IgA nephropathy. Scand J Urol Nephrol 1995;29:5–9.
20.
Heidi Hoi-Yee Ngai, Wai-Hung Sit, Ping-Ping Jiang, et al: Markedly increased urinary preprohaptoglobin and haptoglobin in passive Heymann nephritis: a differential proteomics approach. J Proteome Res 2007;6:3313–3320.
21.
Mathieson PW: Role of the podocyte in glomerular injury. Hong Kong J Nephrol 2001;3:51–55.
22.
Wiggins RC: The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007;71:1205–1214.
23.
Shalhoub RJ: Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974;ii:556–560.
24.
Mathieson PW: Immune dysregulation in minimal change nephropathy. Nephrol Dial Transplant 2003;18(suppl 6):V126–V129.
25.
Sher ER, Surs W, Kam JC, et al: Characterization of T lymphocytes and glucocorticoid receptors in steroid resistant asthma. J. Allergy Clin Immunol 1992;89:285.
26.
Donald Y, Leung M, Martin RJ, Szefler SJ, et al: Dysregulation of interleukin 4, interleukin 5, and interferon γ gene expression in steroid-resistant asthma. J Exp Med 1995;181:33–40.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.